secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuphoria Therapeutics Inc. (NEUP)
CIK:        0001191070
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001213900-24-112016
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.01, 3.02, 3.03, 5.03, 8.01, 5.01, 5.02, 5.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuphoria completes redomiciliation from Australia to Delaware; shares to trade under NEUP
--------------------------------------------------------------------------------

- Effective Dec 23, 2024, Bionomics Ltd. became a wholly-owned subsidiary of Neuphoria; NEUP shares to trade on Nasdaq from Dec 24.
- Exchange ratio: 1 Neuphoria share per 2,160 Bionomics shares or per 12 ADSs; options and warrants converted proportionally.
- Board classified into three classes with staggered terms; Spyros Papapetropoulos CEO, Tim Cunningham CFO, Alan Fisher Chair.
- Neuphoria adopted 2024 Equity Incentive Plan and new anti-takeover charter provisions (classified board, 66 2/3% supermajority, no written consent).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/0001213900-24-112016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1191070/000121390024112016/ea0225663-8k_neupho.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-112016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer